Add like
Add dislike
Add to saved papers

Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue.

BACKGROUND: Histologic distinction of dermatofibrosarcoma protuberans (DFSP) from fibrous histiocytoma (FH) may be difficult. In addition, differential diagnosis is hampered by the lack of appropriate immunohistochemical markers that reliably distinguish between these two entities.

OBJECTIVE: This study is aimed at the introduction of a monoclonal antibody (anti-human progenitor cell antigen-1; anti-CD34) that distinguishes between DFSP and FH in formalin-fixed, paraffin-embedded tissue.

METHODS: Paraffin-embedded specimens of DFSP, FH, and other soft-tissue tumors were investigated for CD34 expression by anti-human progenitor cell antigen-1/alkaline phosphatase-antialkaline phosphatase immunostaining.

RESULTS: Strong CD34 reactivity was present in each DFSP (n = 19) but was consistently absent from FH (n = 45) and other soft-tissue tumors (n = 47).

CONCLUSION: CD34 immunostaining of paraffin-embedded specimens may be useful in differentiating between DFSP and FH.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app